



Claudia Hackl-Zuccarella (Autor)

**Macrophage superoxide anion production in essential hypertension and coronary artery disease patients with Type D personality**

Claudia Hackl-Zuccarella

**Macrophage superoxide anion  
production in essential hypertension  
and coronary artery disease patients  
with Type D personality**



Cuvillier Verlag Göttingen  
Internationaler wissenschaftlicher Fachverlag

<https://cuvillier.de/de/shop/publications/7462>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentzsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen, Germany

Telefon: +49 (0)551 54724-0, E-Mail: [info@cuvillier.de](mailto:info@cuvillier.de), Website: <https://cuvillier.de>



# CONTENTS

ABSTRACT .....	I
ACKNOWLEDGEMENTS .....	II
TABLES .....	VII
FIGURES .....	VIII
ABBREVIATIONS .....	IX

## **1 INTRODUCTION..... 1**

## **2 THEORETICAL BACKGROUND ..... 4**

### **2.1 Macrophages..... 4**

2.1.1 Origin of macrophages .....	5
2.1.2 Classification of macrophages under inflammatory conditions .....	6
2.1.2.1 Classically activated macrophages (M1 phenotype).....	7
2.1.2.2 Alternatively activated macrophages (M2 phenotype) .....	9
2.1.3 Microbicidal activity .....	10
2.1.3.1 Free radicals .....	11
2.1.4 Sources of reactive oxygen species .....	13
2.1.4.1 Phagocytic NADPH oxidase.....	13
2.1.4.1.1 Phagocytic NADPH oxidase components.....	14
2.1.4.1.2 Activation and assembly of the phagocytic NADPH oxidase .....	15
2.1.4.2 Vascular NADPH oxidase .....	17
2.1.4.2.1 Vascular NADPH oxidase components .....	18
2.1.4.2.2 Activation and assembly of the vascular NADPH oxidase.....	19
2.1.5 Bacteria-killing mechanisms of reactive oxygen species.....	20
2.1.6 Clinical relevance of reactive oxygen species.....	20

### **2.2 Essential hypertension ..... 22**

2.2.1 Definition and classification.....	23
2.2.1.1 Total cardiovascular risk.....	24
2.2.2 Diagnostic evaluation .....	26
2.2.2.1 Blood pressure measurement .....	27
2.2.2.1.1 White-coat hypertension .....	30
2.2.2.1.2 Masked hypertension .....	31
2.2.2.2 Medical and family history .....	31



## CONTENTS

---

2.2.2.3 Physical examination .....	32
2.2.2.4 Laboratory investigations.....	32
2.2.3 Risk factors of essential hypertension .....	33
2.2.3.1 Non-modifiable risk factors .....	33
2.2.3.1.1 Age .....	33
2.2.3.1.2 Gender.....	33
2.2.3.1.3 Genetics.....	34
2.2.3.1.4 Ethnicity .....	35
2.2.3.2 Modifiable risk factors .....	35
2.2.3.2.1 Overweight / obesity .....	35
2.2.3.2.2 Alcohol consumption .....	36
2.2.3.2.3 Cigarette smoking .....	37
2.2.3.2.4 Job strain .....	37
2.2.4 Treatment strategies .....	38
2.2.4.1 Lifestyle modifications .....	38
2.2.4.2 Pharmacological therapy.....	39
2.2.5 NADPH oxidase-derived superoxide anion production in hypertension .....	41
2.2.5.1 Animal studies .....	41
2.2.5.1.1 Vascular NADPH oxidase-derived superoxide anion production .....	41
2.2.5.1.2 Phagocytic NADPH oxidase-derived superoxide anion production... ..	45
2.2.5.2 Human studies.....	46
2.2.5.2.1 Vascular NADPH oxidase-derived superoxide anion production .....	46
2.2.5.2.2 Phagocytic NADPH oxidase-derived superoxide anion production... ..	47
<b>2.3 Coronary artery disease.....</b>	<b>49</b>
2.3.1 Atherosclerosis .....	49
2.3.1.1 Pathogenesis of atherosclerosis.....	50
2.3.1.1.1 Response-to-injury hypothesis .....	50
2.3.1.2 The role of monocytes / macrophages .....	54
2.3.1.2.1 Monocyte entry .....	55
2.3.1.2.2 Monocyte differentiation into macrophages .....	55
2.3.1.2.3 Foam cell formation .....	55
2.3.1.2.4 Macrophages in advanced atherosclerosis .....	56
2.3.1.3 Diagnosis of atherosclerosis .....	56
2.3.1.3.1 Carotid intima-media thickness and carotid plaque assessment .....	57
2.3.2 Clinical manifestations of coronary artery disease .....	58
2.3.2.1 Acute coronary syndrome .....	59



## CONTENTS

2.3.2.1.1 Unstable angina pectoris .....	59
2.3.2.1.2 Acute myocardial infarction.....	60
2.3.3 Risk factors for coronary artery disease .....	61
2.3.3.1 Traditional risk factors .....	61
2.3.3.2 Intermediate biological risk factors .....	62
2.3.3.2.1 C-reactive protein.....	62
2.3.3.2.2 Cytokines .....	63
2.3.3.3 Psychosocial risk factors.....	64
2.3.3.3.1 Chronic psychosocial risk factors .....	64
2.3.3.3.2 Episodic psychosocial risk factors .....	67
2.3.3.3.3 Acute psychosocial risk factors.....	68
2.3.4 NADPH oxidase-derived superoxide anion production in atherosclerosis and coronary artery disease .....	69
2.3.4.1 Animal studies .....	69
2.3.4.2 Human studies.....	71
<b>2.4 Type D personality .....</b>	<b>74</b>
2.4.1 Construct of Type D personality .....	75
2.4.1.1 Negative affectivity.....	76
2.4.1.2 Social inhibition .....	77
2.4.1.3 Type D personality and depression.....	78
2.4.1.4 Type D personality as a determinant of psychosocial distress .....	79
2.4.2 Assessment of Type D personality.....	80
2.4.2.1 Type D scale-14 .....	81
2.4.3 Type D personality and cardiovascular health in patients with coronary artery disease .	84
2.4.3.1 Potential biological mechanisms underlying Type D personality and poor cardiac prognosis .....	86
2.4.3.1.1 Dysregulation of the hypothalamic-pituitary-adrenal axis.....	86
2.4.3.1.2 Dysregulation of the autonomic nervous system .....	87
2.4.3.1.3 Dysregulation of the immune system.....	87
2.4.4 NADPH oxidase-derived superoxide anion production in coronary artery disease patients with Type D personality.....	89
<b>2.5 Summary of the theoretical background .....</b>	<b>90</b>
<b>3 AIMS AND HYPOTHESES OF THE EMPIRICAL STUDIES .....</b>	<b>92</b>



<b>4 EMPIRICAL STUDIES .....</b>	<b>95</b>
<b>4.1 Summaries of the empirical studies .....</b>	<b>95</b>
4.1.1 An in vitro method to investigate microbicidal potential of human macrophages for use in psychosomatic research.....	95
4.1.2 Macrophage superoxide anion production in essential hypertension: Associations with biological and psychological cardiovascular risk factors.....	96
4.1.3 Higher macrophage superoxide anion production in coronary artery disease patients with Type D personality .....	97
<b>5 DISCUSSION .....</b>	<b>99</b>
<b>5.1 General Discussion .....</b>	<b>99</b>
5.1.1 Discussion of the results and methodological approaches .....	99
5.1.2 Directions for future research.....	106
<b>6 REFERENCES .....</b>	<b>108</b>
<b>7 APPENDIX .....</b>	<b>157</b>
A1: DS14.....	157
A2: AN IN VITRO METHOD TO INVESTIGATE MICROBICIDAL POTENTIAL OF HUMAN MACROPHAGES FOR USE IN PSYCHOSOMATIC RESEARCH .....	158
A3: MACROPHAGE SUPEROXIDE ANION PRODUCTION IN ESSENTIAL HYPERTENSION: ASSOCIATIONS WITH BIOLOGICAL AND PSYCHOLOGICAL RISK FACTORS.....	187
A4: HIGHER MACROPHAGE SUPEROXIDE ANION PRODUCTION IN CORONARY ARTERY DISEASE (CAD) PATIENTS WITH TYPE D PERSONALITY.....	213